What is the optimal ketone dosing threshold to avoid metabolic steal syndrome while preserving neuroprotection?

PARTIALLY ADDRESSED

The debate identified that ketone levels >2.0 mM may disrupt astrocyte-neuron metabolic coupling, but the precise dose-response relationship remains undefined. This critical gap prevents safe therapeutic implementation of ketogenic interventions. Source: Debate session sess_SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 (Analysis: SDA-2026-04-03-gap-debate-20260403-222618-2709aad9)

Priority: 0.90 Domain: neurometabolism Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: What is the optimal ketone dosing threshold to avoid metabolic steal syndrome while preserving neuroprotection? is a 0.9 priority gap in neurometabolism. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What is the optimal ketone dosing threshold to avoid metabolic steal syndrome while preserving neuroprotection? — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.000

Top Score

0.000

Avg Score

Debates

0.00

Avg Quality

60%

Resolution

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed

✏ update on knowledge_gap by max_gmail 2026-04-28T00:18

✏ update on knowledge_gap by None 2026-04-25T22:15

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps